...
首页> 外文期刊>Biomedicine & pharmacotherapy =: Biomedecine & pharmacotherapie >Novel aspects of in vitro IL-2 or IFN-alpha enhanced NK cytotoxicity of healthy individuals based on NKG2D and CD161 NK cell receptor induction.
【24h】

Novel aspects of in vitro IL-2 or IFN-alpha enhanced NK cytotoxicity of healthy individuals based on NKG2D and CD161 NK cell receptor induction.

机译:基于NKG2D和CD161 NK细胞受体诱导,体外IL-2或IFN-α的新方面增强了健康个体的NK细胞毒性。

获取原文
获取原文并翻译 | 示例

摘要

As IL-2 and IFN-alpha modulate NK cell activity it was of interest to investigate the expression of newly defined NK cell receptors and augmented NK cell activity in healthy individuals after cytokine in vitro treatment. Peripheral blood lymphocytes (PBL) obtained from 31 healthy volunteers treated for 18 h with 200 IU/ml IL-2 and 250 IU/ml IFN-alpha were evaluated for NK cell cytotoxicity. Expression of NKG2D, CD161, CD158a, CD158b receptors was analyzed on CD3CD16+ NK cells, cytotoxic CD16(bright) and regulatory CD16(dim) subsets by FACS flow. The found induced significant in vitro enhancement of NK cell activity by both cytokines is supported by specific cytokine induction in PBL of pSTAT1 and pSTAT5, determined by Western blotting, as well as induction of IRF-1 transcription. Both cytokines induce significant up-regulation of NKG2D expression while only IFN-alpha induced significant up-regulation of CD161, with no alteration in KIR expression by either cytokine on CD3CD16+ NK cells. Investigated cytokines did not induce change in NK cell bright and dim subset distribution. Moreover, we find that, not only cytokine receptor induction on the CD3CD16+ NK cells, but also simultaneous increase in their percentage and/or density on CD16(bright) and CD16(dim) subsets, represent good indicators of receptor cytokine-susceptibility. As the role of NK cells has been shown in the loss of tolerance, infection and cancer, the data obtained in this study may be of help in NK cell profiling, by giving referent values of cytokine-induced novel NK cell receptor expression either in evaluation of these diseases or in immunomonitoring during cytokine immunotherapy.
机译:由于IL-2和IFN-α调节NK细胞的活性,研究细胞因子体外治疗后健康个体中新定义的NK细胞受体的表达和增强的NK细胞活性引起了人们的兴趣。评估从31名健康志愿者获得的外周血淋巴细胞(PBL),分别用200 IU / ml IL-2和250 IU / mlIFN​​-α治疗18小时,以评估NK细胞的细胞毒性。通过FACS流分析NKG2D,CD161,CD158a,CD158b受体在CD3CD16 + NK细胞,细胞毒性CD16(亮)和调节性CD16(暗淡)亚群上的表达。通过Western印迹测定pSTAT1和pSTAT5在PBL中的特异性细胞因子诱导以及IRF-1转录的诱导,证实了两种细胞因子诱导的NK细胞活性的显着体外增强。两种细胞因子均诱导NKG2D表达显着上调,而仅IFN-α诱导CD161显着上调,而CD3CD16 + NK细胞中任一细胞因子均未改变KIR表达。调查的细胞因子未诱导NK细胞明亮和暗淡的亚群分布发生变化。此外,我们发现,不仅在CD3CD16 + NK细胞上诱导了细胞因子受体,而且在CD16(亮)和CD16(dim)亚群上同时增加了它们的百分比和/或密度,这些都是受体细胞因子敏感性的良好指标。由于已经证明了NK细胞在耐受性丧失,感染和癌症中的作用,因此本研究中获得的数据可能通过提供细胞因子诱导的新型NK细胞受体表达的参考值而对NK细胞概况分析有帮助。这些疾病或在细胞因子免疫治疗期间的免疫监测中。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号